NCT06455072View on ClinicalTrials.gov

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Cervical Cancer
Interventions
DRUG

Nituzumab

EGFR monoclonal antibody

DRUG

Serplulimab

PD-1 (programmed death receptor 1) monoclonal antibody

Trial Locations (1)

350011

RECRUITING

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
collaborator

Zhangzhou Municipal Hospital of Fujian Province

OTHER

lead

Fujian Cancer Hospital

OTHER_GOV